Instadip 50/Instadip 100 Use In Pregnancy & Lactation

Pregnancy: Sitagliptin was not teratogenic in rats at oral doses up to 250 mg/kg or in rabbits given up to 125 mg/kg during organogenesis (up to 32 and 22 times, respectively, the human exposure based on the recommended daily adult human dose of 100 mg/day). In rats, a slight increase in the incidence of fetal rib malformations (absent, hypoplastic and wavy ribs) was reported at oral doses of 1000 mg/kg/day (approximately 100 times the human exposure based on the recommended daily adult human dose of 100 mg/day). Slight decreases in mean preweaning body weights of both sexes and postweaning body weight gains of males were reported in the offspring of rat given oral dose of 1000 mg/kg/day. However, reported animal reproduction studies are not always predictive of the human response.
There are no adequate and well-controlled reported studies in pregnant women; therefore, the safety of sitagliptin in pregnant women is not known. Sitagliptin, like other oral antihyperglycemic agents, is not recommended for use in pregnancy.
Nursing Mothers: Sitagliptin is secreted in the milk of lactating rats. It is not known whether sitagliptin is secreted in human milk. Therefore, sitagliptin should not be used by a woman who is nursing.